title: Effect of zaleplon on digoxin pharmacokinetics and pharmacodynamics.
abstract: The pharmacokinetics and pharmacodynamics of digoxin alone and digoxin plus zaleplon were studied. Healthy, nonsmoking men between 18 and 45 years of age were given a single oral dose of digoxin 0.375 mg daily on days 1 through 9. On days 10 through 14, the subjects received digoxin 0.375 mg plus oral zaleplon 10 mg daily. Blood samples were obtained on days 3, 5, 8, 9, and 14, and serum digoxin concentration data were analyzed by model-independent pharmacokinetic methods. Blood pressure, heart rate, PR interval, and QTc interval were recorded to determine the effect of zaleplon on digoxin pharmacodynamics. A total of 20 men completed the study. Maximum serum digoxin concentration and area under the serum digoxin concentration-versus-time curve from 0 to 24 hours met bioequivalence test criteria. There were no significant differences in QTc or PR interval between days 9 (digoxin alone) and 14 (digoxin plus zaleplon), and there were no clinically important changes from baseline to the study's end in vital signs, physical examination findings, or ECG results for individual subjects. Eighteen percent of the subjects who received digoxin alone and 35% of those who received digoxin plus zaleplon reported one or more adverse effects; all were mild and resolved quickly. Zaleplon had no significant effects on selected pharmacokinetic and pharmacodynamic properties of digoxin.
authors.affiliation: Clinical Pharmacology Unit, Hospital La Paz, Madrid, Spain. sanchez@mvax.fmed.aum.es
authors.forename: P
authors.initials: P
authors.lastname: Sanchez Garcia
authors.forename: I
authors.initials: I
authors.lastname: Paty
authors.forename: C A
authors.initials: CA
authors.lastname: Leister
authors.forename: P
authors.initials: P
authors.lastname: Guerra
authors.forename: J
authors.initials: J
authors.lastname: Frías
authors.forename: L E
authors.initials: LE
authors.lastname: García Pérez
authors.forename: M
authors.initials: M
authors.lastname: Darwish
mesh_terms: D000081:Acetamides / Q000493:pharmacokinetics*; D000328:Adult; D000704:Analysis of Variance; D002316:Cardiotonic Agents / Q000097:blood / Q000493:pharmacokinetics*; D016001:Confidence Intervals; D004077:Digoxin / Q000097:blood / Q000493:pharmacokinetics*; D004347:Drug Interactions; D006439:Hemodynamics / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D006993:Hypnotics and Sedatives / Q000493:pharmacokinetics*; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000493:pharmacokinetics*
chemical_list: D000081:Acetamides; D002316:Cardiotonic Agents; D006993:Hypnotics and Sedatives; D011743:Pyrimidines; D004077:Digoxin; C085665:zaleplon